Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
  • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D207/24—Oxygen or sulfur atoms
  • C07D207/26—2-Pyrrolidones
  • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
  • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/06—Antimigraine agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • C—CHEMISTRY; METALLURGY
  • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
  • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
  • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
  • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
  • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
  • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
  • C04B35/632—Organic additives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C233/00—Carboxylic acid amides
  • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
  • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
  • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C233/00—Carboxylic acid amides
  • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
  • C07C233/62—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C233/00—Carboxylic acid amides
  • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
  • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
  • C07C237/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
  • C07C271/06—Esters of carbamic acids
  • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
  • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
  • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
  • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
  • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
  • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
  • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
  • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
  • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/56—Ring systems containing three or more rings
  • C07D209/58—[b]- or [c]-condensed
  • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/62—Oxygen or sulfur atoms
  • C07D213/70—Sulfur atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
  • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
  • C07D221/04—Ortho- or peri-condensed ring systems
  • C07D221/06—Ring systems of three rings
  • C07D221/10—Aza-phenanthrenes
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
  • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D233/30—Oxygen or sulfur atoms
  • C07D233/42—Sulfur atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D233/84—Sulfur atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
  • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
  • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
  • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
  • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
  • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
  • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
  • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
  • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
  • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
  • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
  • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
  • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
  • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
  • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
  • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
  • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
  • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
  • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
  • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
  • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
  • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
  • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
  • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
  • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
  • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
  • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
  • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
  • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
  • C07D333/58—Radicals substituted by nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
  • C07D333/74—Naphthothiophenes
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
  • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
  • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
  • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
  • C07D335/08—Naphthothiopyrans; Hydrogenated naphthothiopyrans
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
  • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
  • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
  • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D495/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
  • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
  • C07D495/14—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2601/00—Systems containing only non-condensed rings
  • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2601/00—Systems containing only non-condensed rings
  • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
  • C07C2601/14—The ring being saturated
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2602/00—Systems containing two condensed rings
  • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
  • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
  • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2602/00—Systems containing two condensed rings
  • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
  • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
  • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Definitions

• the present invention relates to new substituted cyclic derivatives, their preparation process and the pharmaceutical compositions containing them.
• Benzo [è] thiophenic compounds have also been described as anti-inflammatory (US 5350748, US 5068248) or anti-cancer agents (Heterocycles, 1985, 23 (5), pp. 1173-80).
• the compounds of the present invention are new and have very interesting pharmacological characteristics concerning the melatoninergic receptors.
• melatonin N-acetyl-5-methoxytryptamine
• melatonin N-acetyl-5-methoxytryptamine
• it has a fairly short half-life due to rapid metabolism. It is therefore very interesting to be able to make available to the clinician analogues of melatonin, metabolically more stable and having an agonist or antagonist character, from which one can expect a therapeutic effect greater than that of the hormone itself.
• the ligands of the melatoninergic system have interesting properties pharmacological on the central nervous system, in particular anxiolytics and antipsychotics (Neuropharmacology of Pineal Sécrétions, 1990, 8 (3-4), pp 264-272) and analgesics (Pharmacopsychiat., 1987, 20, pp 222-223) as well as for treatment of Parkinson's disease (J. Neurosurg. 1985, 63, pp 321-341) and Alzheimer's (Brain Research, 1990, 528, pp 170-174).
• the compounds of the present invention in addition to their novelty, show a very strong affinity for the melatonin receptors and / or a selectivity for one or the other of the melatoninergic receptor subtypes.
• the present invention relates more particularly to the compounds of formula (I)
• ⁇ A represents:
• X represents an oxygen, sulfur or nitrogen atom, or a group C (H) q (where q is 0, 1 or 2), or NRo (in which Ro represents a hydrogen atom, a alkyl (C ⁇ -C6) linear or branched, aryl, aryl (C ⁇ -C6) linear or branched, or SO 2 Ph), Y represents a nitrogen atom or a group C (H) q (where q is 0, 1 or 2),
• Z represents a nitrogen atom or a group C (H) q (where q is 0, 1 or 2), X, Y and Z cannot simultaneously represent three heteroatoms,
• B represents a benzene or pyridine ring
• R substitutes the ring B and R 'replaces the ring containing the groups X, Y and Z, or R and R' substitute the ring B
• T represents an oxygen or sulfur atom, or a group C (H) q (where q is 0, 1 or 2),
• n is an integer such that 0 ⁇ n ⁇ 3,
• W represents an oxygen, sulfur or nitrogen atom, or a group [C (H) q ] p (where q is 0, 1 or 2, and p is 1 or 2), or NRo where Ro is as defined above,
• ring systems of formulas (II), (III) and (IV) and the biphenyl group may or may not be substituted (in addition to the substituents R and R ') by 1 to 6 radicals, identical or different, chosen from R a , OR a , CORa, COOR a , OCOR a , OSO 2 CF 3 cyano, nitro or halogen atoms,
• R a represents a hydrogen atom, an alkyl group (C ⁇ -C 6 ) linear or branched substituted or not, alkenyl (C 2 -C 6 ) linear or branched substituted or not, alkynyl (C 2 -C 6 ) linear or branched substituted or not, polyhaloalkyl (C ⁇ -C 6 ) linear or branched, cycloalkyle (C 3 -C 8 ) substituted or not, cycloalkyle (C 3 -C 8 ) alkyl (C ⁇ -C 6 ) linear or branched substituted or not , cycloalkenyl (C 3 -C 8 ) substituted or not, cycloalkenyl (C 3 -C 8 ) alkyl (C ⁇ -C 6 ) linear or branched substituted or not, aryl, arylalkyl (C ⁇ -C 6 ) linear or branched, arylalkenyl ( C ⁇ -C 6 )
• R represents: - a group of formula (V):
• R 1 represents a halogen atom, a group R a , ORa, COR a or COOR a where R a has the same definition as above,
• R cannot represent a group SO 3 H
• R' a and R" a can take all the values of Ra and can also form, with the nitrogen atom which carries them a cyclic group containing 5 to 10 links which may comprise, in addition to the nitrogen atom, one to three heteroatoms chosen from oxygen, sulfur and nitrogen, or forms with two adjacent carbon atoms of the ring structure A which carries it, when A represents a ring system of formula (II) or (III) or a biphenyl group,
• r and R a are as defined above, the ring formed containing from 5 to 7 atoms and possibly containing 1 to 3 heteroatoms chosen from nitrogen, sulfur and oxygen, one or more unsaturations, and being optionally substituted by one or more radicals, identical or different, chosen from R a , OR a , COR a , COOR a ,
• G represents an alkylene chain - (CH) t - (in which t is an integer such as 0 ⁇ t ⁇ 4), optionally substituted by one or more radicals, identical or different, chosen among R a , OR a , COOR a , COR a (in which R a is as defined above) or halogen atoms, RR
• R 2 represents a group - N— C M - R 'a, - N— C n— NR' a R "., - C N - NR 'a R" a
• R ' a and R " a being able to form, with the nitrogen atom which carries them, a cyclic group as defined above,
• heterocycloalkyl means any saturated mono or polycyclic group containing from 5 to 10 atoms containing 1 to 3 heteroatoms chosen from nitrogen, oxygen or sulfur,
• heterocycloalkenyl means any non-aromatic mono or polycyclic group containing one or more unsaturations, containing from 5 to 10 atoms and possibly containing 1 to 3 heteroatoms chosen from nitrogen, oxygen or sulfur,
• alkyl alkenyl
• alkynyl alkynyl
• substituents identical or different, chosen from hydroxy, linear or branched alkoxy (CC 6 ), linear or branched (Ci -Ce) alkyl, linear or branched polyhaloalkyl (C ⁇ -C 6 ), amino or halogen atoms,
• cycloalkyle means that the cyclic part of these groups is substituted by one or more radicals, identical or different, selected from hydroxy, alkoxy (C ⁇ -C6) linear or branched alkyl (C ⁇ -C6) linear or branched polyhaloalkyl (Ci-Ce) linear or branched, amino or carbon halogen
• aryl means any mono or polycyclic aromatic group containing 6 to 22 carbon atoms, as well as the biphenyl group
• heteroaryl means any mono or polycyclic aromatic group containing from 5 to 10 atoms containing 1 to 3 heteroatoms chosen from nitrogen, oxygen or sulfur,
• aryl and heteroaryl groups which may be substituted by one or more radicals, identical or different, chosen from hydroxy, linear or branched (Ci-Ce) alkoxy, linear or branched (C ⁇ -C 6 ) alkyl, polyhaloalkyl (C ⁇ -C 6 ) linear or branched, cyano, nitro, amino or halogen atoms,
• R 2 cannot represent a group -NHCOR e in which Re is a group containing a heterocycle mono or bicyclic aromatic or not,
• hydrochloric hydrobromic, sulfuric, phosphonic, acetic, trifluoroacetic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, tartaric, maleic, citric, ascorbic, methanesulfonic, camphoric acids. , oxalic, etc.
• the preferred compounds of the invention are those for which A represents a ring system of formula (II) or (III) and more particularly of formula (II 1 ) B (II 1 ) in which
• the invention relates to the compounds for which A, unsubstituted or substituted by a single substituent (in addition to R and R ′) preferably in position 2 (formula IF) or
• formula II I ' represents a (II') in which B, X and the representation have the same meaning as above, such as for example benzothiophene, dihydrobenzothiophene, benzofuran, dihydrobenzofuran, indole, indoline, indane, indene, azaindole, thienopy ⁇ dine or furopy ⁇ dine,
• the invention relates to the compounds for which A, of formula (IF) or (IIF) is substituted by R in positions 5 (formula IF) or 7 (formula IIF) and by R 'in position 3 ( formula IF) or 1 or 2 (formula IIF)
• the preferred substituents R of the invention are those represented by a group of formula (V), (VI) or -NR ' a R " a (where R' a and R" a are defined as above) More advantageously, the preferred substituents R of the invention are those represented by a group of formula (V) (where r is 0 and R 1 represents a group R a as defined above), a group NR ' a R " a (where R ' a and R " a are as defined above), or a group of formula (VI) where E represents a group in
• the preferred substituents R of the invention are those represented by a group of formula (V) where r is 0 and R 1 represents an alkyl, polyhaloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl group , aryl, arylalkyl, heteroaryl, or heteroarylalkyl, for example methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secbutyl, tertbutyl, pentyl, isopentyl, hexyl, trifluoromethyl, vinyl, allyl, propargyl, phenyl, naphthyl, benzyl, phenethyl , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexyl,
• R ′ of the invention are those for which G represents an alkylene chain - (CH 2 ) t - unsubstituted or substituted where t is 2 or 3, and R 2 represents a group
• R ′ of the invention are those for which G represents a group - (CH 2 ) t - where t is 2 or 3, and R 2 represents a group
• R' a represents an alkyl, polyhaloalkyl, alkenyl, alkynyl group,
• O represents an alkyl, polyhaloalkyl, alkenyl, alkynyl, cycloakyl, cycloalkenyl, cycloakylalkyl, cycloalkenylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl group, such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, butyl , hexyl, trifluoromethyl, vinyl, allyl, propargyl, phenyl, naphthyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, methylcyclopropyl, ethylcyclopropyl, furyl, thienyl, pyridyl, furylmethyl, pyridyl.
• the preferred compounds of the invention are those for which A represents a ring system of formula (IF) or (IIF) and R represents a group of formula (V), (VI) or -NR ' a R " a .
• the invention relates to the compounds for which:
• A represents a group of formula (IF) or (IIF) substituted in position 5 (formula IF) or 7
• the preferred compounds of the invention are those for which A represents a ring system of formula (IF) or (IIF) optionally substituted (in addition to R and R ') by a substituent in position 2 (formula IF) or in position 3 (formula IIF), substituted in positions 5 (formula IF) or 7 (formula IIF) by R and in positions 3 (formula IF) or
• R represents a group -SR a , NR ' a R " a (where R a ' and R" a are defined as above), or a group of formula (VI) where E represents a group - S - or - N - in
• R 2 represents a grouping - ⁇ - C - R ', - N - C - NR' R "or - C - NR 'R"
• R a , R ' a and R " a are as defined above.
• the invention relates to the (dihydro) benzothiophene, (dihydro) benzofuran, indole, indoline, indene, indane, azaindole, thieno or furopyridine optionally substituted in position 2, and the dihydronaphthalene, tetrahydronaphthalene, naphthalene or chromane optionally substituted in position 2 position 3, substituted in 5 (7 respectively) by a group -SR a or -NR ' a R " a where R' a and R" a , identical or different, represent a hydrogen atom, an alkyl, polyhaloalkyl, alkenyl group , alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylakyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, such as methyl,
• the preferred compounds of the invention are naphthalenes optionally substituted in position 3, substituted in 7 by a thioalkyl group such as for example thiomethyl, thioethyl, thiopropyl, and substituted in 1 by a group - (CH 2 ) t - N ⁇ COR ' a where t is 2 or 3 and R' a represents an alkyl, polyhaloalkyl, cycloalkyl group such as for example methyl, ethyl, propyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
• a thioalkyl group such as for example thiomethyl, thioethyl, thiopropyl
• R' a represents an alkyl, polyhaloalkyl, cycloalkyl group such as for example methyl, ethyl, propyl, trifluoromethyl,
• the invention relates especially to compounds of formula (I) which are:
• the invention also extends to the process for preparing the compounds of formula (I) characterized in that the compound of formula (VIII) is used as starting material -
• a - R ' wherein A and R' are as defined hereinbefore, which is subjected to demethylation using conventional agents such as HBr, A1C1 3, AlBr 3, BBr 3 or binary systems Lewis acid / nucleophile as AlCl / PhCH 2 SH, or BBr 3 / Me 2 S for example, to obtain the compound of formula (IX):
• Y represents a group C (H) q (where q is 0, 1 or 2) or a bond
• X represents an atom of oxygen, of nitrogen or sulfur or a group C (H) q (where q is 0, 1 or 2) or NRo (where Ro is as defined above) it being understood that when X "represents a nitrogen atom or a group NRo then Y '' represents a bond, from a compound of formula (XIV)
• Hal - A- R '(XX) in which A and R' are defined as above and Hal represents a halogen atom the compounds of formula (XX) being obtainable by exchange reactions such as for example the treatment of '' a derivative chlorinated by KF within dimethylformamide to lead to the corresponding fluorinated derivative, or the treatment of a brominated derivative by K1 in the presence of copper salts to lead to the corresponding iodized derivative, compounds of formula (XX) which may moreover be obtained from compounds of formula (XXi) or (XX 2 ):
• compound of formula (XXI) which can also be obtained by conventional lithiation techniques from the halogen derivative of formula (XX), or via the corresponding vinyl derivative (obtained from the compound of formula (XX) by the action of vinyltributyltin and palladium tetrakis) subjected to ozonolysis, or else by direct formylation of the nucleus A according to a Vilsmeier reaction for example,
• the starting compounds (VIII) are either commercial or described in the literature, for example in applications EP0447285, EP0527687, EP0562956, EP0591057, EP0662471, EP0745586, EP0709371, EP0745583, EP0721938, EP0745584, EP07376852, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682
• the invention also relates to the process for preparing the compounds of formula (I) for which R represents a cycle of formula (VI) characterized in that the compounds of formula (I / a) to ( V ⁇ ), that one cyc se according to methods described in the literature, as for example in the applications EP0708099 or WO9732871
• the compounds of the invention and the pharmaceutical compositions containing them prove to be useful for the treatment of disorders of the melatoninergic system
• the invention also relates to the compounds of formula (XXA), special case of the compounds of formula (XX)
• Hal represents a halogen atom (fluorine, chlorine, bromine, iodine)
• X A represents a sulfur atom, or a group C (H) q (where q is 0, 1 or 2) or NRo (in which Ro is as defined above), and the representation _ has the same meaning as previously,
• Y ⁇ and Z identical or different represent an oxygen or sulfur atom, or a group ( ' (H), (or qv aut 0, 1 or 2), and the representation, has the same
• R ⁇ represents a group GR A in which G is as defined above and R 2 A
• the compounds will preferably be used in the treatment of seasonal depressions, sleep disorders, cardiovascular pathologies, insomnia and fatigue due to jetlag, appetite disorders and obesity.
• the compounds will be used in the treatment of seasonal depressions and sleep disorders.
• the present invention also relates to pharmaceutical compositions containing at least one compound of formula (I) alone or in combination with one or more pharmaceutically acceptable excipients.
• compositions according to the invention there may be mentioned, more particularly those which are suitable for oral, parenteral, nasal, per. or transcutaneous, rectal, perlingual, ocular or respiratory and in particular simple or coated tablets, sublingual tablets, sachets, packages, capsules, glossettes, tablets, suppositories, creams, ointments, dermal gels, and oral or injectable ampoules.
• the dosage varies according to the sex, age and weight of the patient, the route of administration, the nature of the therapeutic indication, or possibly associated treatments and ranges between 0.01 mg and 1 g per 24 hours in 1 or more takes.
• stage B the acid obtained in stage B (10 g, 52 mmol) is heated at 70 ° C for 2 hours in the presence of 10 times by mass of polyphosphoric acid (100 g).
• the reaction mixture is hydrolyzed in ice and then extracted with ethyl ether.
• the organic phase is washed with water, dried over magnesium sulfate and evaporated.
• the residue is purified by chromatography on silica gel (eluent: dichloromethane) to yield the expected tetralone in the form of a yellow oil.
• stage D The compound obtained in stage D (2 g, 9.29 mmol) is heated to 230 ° C in the presence of sulfur (357 mg, 11.1 mmol) for 16 hours. After hydrolysis and extraction with ethyl acetate, the organic phase is washed with water, dried over magnesium sulfate and evaporated. The residue is purified by chromatography on silica gel (eluent: cyclohexane / ethyl acetate 80/20) to yield the corresponding flavored compound in the form of a beige solid.
• Chlorine (10 mmol) is bubbled into dichlorophenylphosphine at a flow such that the reaction temperature is maintained between 70 and 80 ° C. After complete addition of the chlorine, the phenylphosphine tetrachloride thus obtained is a pale yellow liquid. 10 mmol of the product obtained in Preparation 5 are added in a single portion, and the reaction mixture is heated to 160 ° C overnight. After cooling, the solution is poured into a water / ice mixture (20 ml) and neutralized with a 50% aqueous sodium hydroxide solution. After extraction with ether, the organic phases are dried and concentrated under reduced pressure to give a residue which is chromatographed on silica gel in order to obtain the pure title product.
• T ⁇ phenylphosphine (10 mmol) and acetonitrile (70 ml) are added to a 1 ⁇ 0 ml flask fitted with a dropping funnel, a condenser surmounted by a tube filled with calcium chloride and a mechanical stirrer. ml)
• the solution is cooled using an ice bath while maintaining stirring and the bromine (10 mmol) is added. At the end of the addition, the ice bath is removed and then the product obtained is added.
• preparations 161 to 185 the procedure is carried out as in Preparation 160, but replacing the product of Preparation 134 with the appropriate substrate.
• Preparation 163 N- [2- (7-Iodo-1-naphthyl) ethyl] -N-methyl-N'-propylurea Starting product: Preparation 137
• Preparation 164 methyl 2- (7-Iodo-1-naphthyl) -3 - [(2,2,2-trifluoroacetyl) amino] propanoate
• Preparations 225 to 235 are obtained by proceeding as in Preparation 224.
• Preparations 236 to 238 are obtained by proceeding as in Preparation 134.
• Preparation 236 N- [2- (7-Bromo-1,2,3,4-tetrahydro-1-naphthalenyl) ethyl] acetamide
• Preparations 247 to 257 are obtained by proceeding as in Preparation 224.
• the diphenyl ether is evaporated under reduced pressure until a solution of approximately 2 ml is obtained.
• the 2 ml of still hot distillate are carefully poured into 50 ml of hexane to give, after cooling, a solid isolated by filtration.
• the solid thus collected is added to a solution of potassium hydroxide (380 mg) dissolved in a water / methanol mixture (1 ml / 10 ml).
• the solution is brought to reflux for 12 hours then cooled and concentrated under reduced pressure.
• the residue is taken up with 20 ml of chloroform and extracted 3 times with water.
• the organic phase is dried over magnesium sulfate, filtered and concentrated under reduced pressure.
• the residue is chromatographed on silica gel to yield the title product.
• Examples 11 to 36 are obtained by proceeding as in Example 10 from the appropriate hydroxylated compound.
• Example 37 the procedure is as in Example 8, replacing ethanethiol with the appropriate thiol and N- [2- (7-hydroxy-1-naphthyl) ethyl] acetamide with the appropriate hydroxylated compound.
• EXAMPLE 46 4 - ⁇ [8- (2- (Acetyamino) ethyl) -1-propenyl-2-naphthyl] thio ⁇ butanoate
• EXAMPLE 57 N-CyclobutyI-N '- ⁇ 2- [7- (2-propynylthio) -l-naphthyl] ethyl ⁇ urea Starting materials: Preparation 23 and 2-propynyl-l -thiol
• EXAMPLE 58 N-Isopropyl-N '- ⁇ 2- [7 - ((4- (trifluoromethyl) benzyl) thio) -1-naphthyl] ethyl ⁇ urea
• EXAMPLE 66 2 - ⁇ [7- (Cyclopropylmethyl) thio] -1-naphthyl ⁇ -3 - [(2,2,2-trinuoroacetyl) aminojpropanoate Starting materials • Preparation 30 and cyclopropylmethylthwl
• EXAMPLE 67 O- ⁇ 2 [7- (2-Propynylthio) -1-naphthyl] methyl ⁇ -N-acetyl-hydroxyIamine
• EXAMPLE 80 2 - ⁇ [8- (2-
• EXAMPLE 113 N- ⁇ 2- [5- (2-Cyclohexenylthio) -2-phenyI-2H-pyrrolo [2, J-é] pyridin-3-yl] ethyl ⁇ acetamide Starting materials: Preparation 73 and 2-cyclohexeneth ⁇ ol
• EXAMPLE 114 2 - ⁇ [3- (2 - [(Cyclobutylcarbonyl) amino] ethyl) -2H-pyrrolo [2, -6] pyridin-5-yl] thio ⁇ methyl benzoate
• Example 43 The product obtained in Example 43 (10 mmol) is added to a 0.5M aqueous solution of sodium periodate (21 ml, 10.5 mmol) at 0 ° C. Stirring at 0-5 ° C is continued overnight. The solution is filtered and the filtrate extracted with chloroform.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Diabetes (AREA)
• Pain & Pain Management (AREA)
• Ceramic Engineering (AREA)
• Manufacturing & Machinery (AREA)
• Endocrinology (AREA)
• Psychiatry (AREA)
• Reproductive Health (AREA)
• Obesity (AREA)
• Structural Engineering (AREA)
• Materials Engineering (AREA)
• Hematology (AREA)
• Inorganic Chemistry (AREA)
• Anesthesiology (AREA)
• Pregnancy & Childbirth (AREA)
• Gynecology & Obstetrics (AREA)
• Psychology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Emergency Medicine (AREA)
• Hospice & Palliative Care (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Indole Compounds (AREA)

Priority Applications (13)

Applications Claiming Priority (2)

Related Child Applications (3)

Publications (1)

Family

ID=9526252

Family Applications (2)

Family Applications After (1)

Country Status (18)

Cited By (21)

Families Citing this family (24)

Citations (6)

Family Cites Families (10)

• 1998
  • 1998-05-12 FR FR9805957A patent/FR2778662B1/fr not_active Expired - Fee Related
• 1999
  • 1999-05-10 ES ES99918036T patent/ES2255260T3/es not_active Expired - Lifetime
  • 1999-05-10 CN CN99806830A patent/CN1304400A/zh active Pending
  • 1999-05-10 AU AU36104/99A patent/AU747301B2/en not_active Ceased
  • 1999-05-10 CA CA002331870A patent/CA2331870C/fr not_active Expired - Fee Related
  • 1999-05-10 DE DE69933149T patent/DE69933149T2/de not_active Expired - Fee Related
  • 1999-05-10 NZ NZ507691A patent/NZ507691A/en unknown
  • 1999-05-10 HU HU0101813A patent/HUP0101813A3/hu unknown
  • 1999-05-10 AU AU36103/99A patent/AU748567B2/en not_active Ceased
  • 1999-05-10 ES ES99918037T patent/ES2255261T3/es not_active Expired - Lifetime
  • 1999-05-10 CA CA002331877A patent/CA2331877C/fr not_active Expired - Fee Related
  • 1999-05-10 DE DE69933147T patent/DE69933147T2/de not_active Expired - Fee Related
  • 1999-05-10 WO PCT/FR1999/001100 patent/WO1999058495A1/fr not_active Ceased
  • 1999-05-10 DK DK99918036T patent/DK1077927T3/da active
  • 1999-05-10 JP JP2000548299A patent/JP2002514619A/ja active Pending
  • 1999-05-10 AT AT99918036T patent/ATE312072T1/de not_active IP Right Cessation
  • 1999-05-10 EP EP99918037A patent/EP1077928B1/fr not_active Expired - Lifetime
  • 1999-05-10 WO PCT/FR1999/001101 patent/WO1999058496A1/fr not_active Ceased
  • 1999-05-10 BR BR9911783-5A patent/BR9911783A/pt not_active Application Discontinuation
  • 1999-05-10 EP EP99918036A patent/EP1077927B1/fr not_active Expired - Lifetime
  • 1999-05-10 DK DK99918037T patent/DK1077928T3/da active
  • 1999-05-10 JP JP2000548300A patent/JP2002514620A/ja active Pending
  • 1999-05-10 PL PL99344048A patent/PL195613B1/pl unknown
  • 1999-05-10 HU HU0101800A patent/HUP0101800A3/hu unknown
  • 1999-05-10 CN CN99806053A patent/CN1300277A/zh active Pending
  • 1999-05-10 PL PL99344012A patent/PL344012A1/xx unknown
  • 1999-05-10 AT AT99918037T patent/ATE312073T1/de not_active IP Right Cessation
  • 1999-05-10 US US09/700,056 patent/US6605632B1/en not_active Expired - Fee Related
  • 1999-05-10 BR BR9911771-1A patent/BR9911771A/pt not_active Application Discontinuation
  • 1999-05-10 US US09/700,098 patent/US6872851B1/en not_active Expired - Fee Related
  • 1999-05-10 NZ NZ507692A patent/NZ507692A/en unknown
• 2000
  • 2000-11-10 ZA ZA200006528A patent/ZA200006528B/en unknown
  • 2000-11-10 ZA ZA200006529A patent/ZA200006529B/en unknown
  • 2000-11-13 NO NO20005715A patent/NO20005715L/no not_active Application Discontinuation
  • 2000-11-13 NO NO20005714A patent/NO20005714L/no not_active Application Discontinuation
• 2003
  • 2003-06-16 US US10/462,326 patent/US20040002490A1/en not_active Abandoned
  • 2003-06-16 US US10/462,331 patent/US7183318B2/en not_active Expired - Fee Related
• 2004
  • 2004-09-23 US US10/947,757 patent/US7126012B2/en not_active Expired - Fee Related
  • 2004-09-23 US US10/948,410 patent/US7115752B2/en not_active Expired - Fee Related

Patent Citations (6)

Also Published As

Similar Documents

Legal Events